Alterations of pre-mRNA splicing in cancer

被引:147
作者
Kalnina, Z [1 ]
Zayakin, P [1 ]
Silina, K [1 ]
Line, A [1 ]
机构
[1] Latvian State Univ, Biomed Res & Study Ctr, LV-1067 Riga, Latvia
关键词
D O I
10.1002/gcc.20156
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recent genomewide analyses of alternative splicing (AS) indicate that up to 70% of human genes may have alternative splice forms, suggesting that AS together with various posttranslational modifications plays a major role in the production of proteome complexity. Splice-site selection under normal physiological conditions is regulated in the developmental stage in a tissue type-specific manner by changing the concentrations and the activity of splicing regulatory proteins. Whereas spliceosomal errors resulting in the production of aberrant transcripts rarely occur in normal cells, they seem to be an intrinsic property of cancer cells. Changes in splice-site selection have been observed in various types of cancer and may affect genes implicated in tumor progression (for example, CD44, MDM12, and FHIT) and in susceptibility to cancer (for example, BRCA I and APC. Splicing defects can arise from inherited or somatic mutations in cis-acting regulatory elements (splice donor, acceptor and branch sites, and exonic and intronic splicing enhancers and silencers) or variations in the composition, concentration, localization, and activity of regulatory proteins. This may lead to altered efficiency of splice-site recognition, resulting in overexpression or down-regulation of certain splice variants, a switch in splice-site usage, or failure to recognize splice sites correctly, resulting in cancer-specific splice forms. At least in some cases, changes in splicing have been shown to play a functionally significant role in tumorigenesis, either by inactivating tumor suppressors or by gain of function of proteins promoting tumor development. Moreover, cancer-specific splicing events may generate novel epitopes that can be recognized by the host's immune system as cancer specific and may serve as targets for immunotherapy. Thus, the identification of cancer-specific splice forms provides a novel source for the discovery of diagnostic or prognostic biomarkers and tumor antigens suitable as targets for therapeutic intervention. (C) 2005 Wiley-Liss, Inc.
引用
收藏
页码:342 / 357
页数:16
相关论文
共 107 条
[11]   Analysis of canonical and non-canonical splice sites in mammalian genomes [J].
Burset, M ;
Seledtsov, IA ;
Solovyev, VV .
NUCLEIC ACIDS RESEARCH, 2000, 28 (21) :4364-4375
[12]   Killing the messenger: new insights into nonsense-mediated mRNA decay [J].
Byers, PH .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (01) :3-6
[13]   Listening to silence and understanding nonsense: Exonic mutations that affect splicing [J].
Cartegni, L ;
Chew, SL ;
Krainer, AR .
NATURE REVIEWS GENETICS, 2002, 3 (04) :285-298
[14]   A novel aberrant splice site mutation in the APC gene [J].
Charames, GS ;
Cheng, H ;
Gilpin, CA ;
Hunter, AGW ;
Berk, T ;
Bapat, B .
JOURNAL OF MEDICAL GENETICS, 2002, 39 (10) :754-757
[15]  
Collesi C, 1996, MOL CELL BIOL, V16, P5518
[16]   The HGF receptor family: Unconventional signal transducers for invasive cell growth [J].
Comoglio, PM ;
Boccaccio, C .
GENES TO CELLS, 1996, 1 (04) :347-354
[17]   TO METASTASIZE OR NOT - SELECTION OF CD44 SPLICE SITES [J].
COOPER, DL ;
DOUGHERTY, GJ .
NATURE MEDICINE, 1995, 1 (07) :635-637
[18]   Nova regulates GABAA receptor γ2 alternative splicing via a distal downstream UCAU-rich intronic splicing enhancer [J].
Dredge, BK ;
Darnell, RB .
MOLECULAR AND CELLULAR BIOLOGY, 2003, 23 (13) :4687-4700
[19]   The splice of life: Alternative splicing and neurological disease [J].
Dredge, BK ;
Polydorides, AD ;
Darnell, RB .
NATURE REVIEWS NEUROSCIENCE, 2001, 2 (01) :43-50
[20]   Diagnostic and therapeutic applications of recombinant antibodies: Targeting the extra-domain B of fibronectin, A marker of tumor angiogenesis [J].
Ebbinghaus, C ;
Scheuermann, J ;
Neri, D ;
Elia, G .
CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (13) :1537-1549